This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo
Back to library search

Standing The Test of Time: Important Considerations in Long-Term Partnering Transactions

Abstract

In the integrated global economy that has emerged over the last two decades, companies in all industries require a network of partners to discover, develop, manufacture, market, sell, supply and distribute products to global markets. Long-term strategic partnerships with high levels of interdependence can be among the best opportunities for a company to leverage and exploit its core capabilities and assets. However, these partnerships also present substantial challenges that require the highest level of practical and insightful legal counsel to guide their design, negotiation and day-to-day administration.

PLS LogoCopyright & permissions

Authors

Portrait image of Gilbert Labrucherie
Gilbert Labrucherie
Senior Vice President and General Counsel, Nektar Therapeutics, USA

Gil M. Labrucherie joined Nektar in September 2005 as Vice President of Corporate Legal. Prior to joining Nektar, from October 2000 to September 2005, Mr. Labrucherie was Vice President of Corporate Development at E2open, Inc., where he was responsible for global corporate alliances and merger and acquisition activity. Prior to E2open, he was the Senior Director of Corporate Development at AltaVista Company, an Internet search company, where he was responsible for merger and acquisition transactions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati and Graham & James (DLA Piper Rudnick). Mr. Labrucherie received his J.D. from the Berkeley Law School, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis.

Companies

Nektar Therapeutics

Nektar Therapeutics

Nektar Therapeutics (Nasdaq: NKTR) is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

Related Papers

Implementing Effective Compliance Programs in Jurisdictions Where the Rule of Law is Weak
Multinational organizations increasingly operate in jurisdictions where the rule of law is weak, inconsistently enforced, or subject to political and economic influence. For pharmaceutical and biotechnology companies, these environments present...Read more
Portrait image of Fabiana Lacerca-Allen
Fabiana Lacerca-Allen
Chief Compliance Officer, Cipla, USA
Portrait image of Valentina Lacerca-Allen
Valentina Lacerca-Allen
Title Marketing/ Communication Specialist, Ethiprax LLC., USA
March-In Rights at a Crossroad: What Biopharma Needs To Know Under Trump Administration
Few pieces of legislation have shaped the modern innovation landscape as profoundly as the Bayh-Dole Act of 1980. By allowing universities, small businesses, and non-profit organizations to retain ownership...Read more
Portrait image of Joanna Brougher
Joanna Brougher
Owner & Principal, BioPharma Law Group PLLC, USA
Portrait image of Bhavya Bhardwaj
Bhavya Bhardwaj
Student, University of Pennsylvania, USA
Patent Strategies for Attenuated Pathogen Vaccines
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
Portrait image of David Dolberg
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA
Ways to Avoid Having your Patents Cellected*
The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more
Portrait image of Tom Irving
Tom Irving
Partner, Marbury Law Group, USA
Portrait image of Xiaoguang Michelle Gao
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel , Eli Lilly and Company, USA
Portrait image of Michelle E. O'Brien
Michelle E. O'Brien
Partner, Marbury Law Group, USA